Preoperative Esophageal Stenting and 5-Year Survival in Patients Undergoing Esophagectomy for Esophageal Cancer : a Population-Based Nationwide Study from Finland
on behalf of the FINEGO group; Helminen, Olli; Sihvo, Eero; Helmiö, Mika; Huhta, Heikki; Kallio, Raija; Koivukangas, Vesa; Kokkola, Arto; Laine, Simo; Lietzen, Elina; Meriläinen, Sanna; Pohjanen, Vesa Matti; Rantanen, Tuomo; Ristimäki, Ari; Räsänen, Jari V.; Saarnio, Juha; Toikkanen, Vesa; Tyrväinen, Tuula; Valtola, Antti; Kauppila, Joonas H. (2023-03)
on behalf of the FINEGO group
Helminen, Olli
Sihvo, Eero
Helmiö, Mika
Huhta, Heikki
Kallio, Raija
Koivukangas, Vesa
Kokkola, Arto
Laine, Simo
Lietzen, Elina
Meriläinen, Sanna
Pohjanen, Vesa Matti
Rantanen, Tuomo
Ristimäki, Ari
Räsänen, Jari V.
Saarnio, Juha
Toikkanen, Vesa
Tyrväinen, Tuula
Valtola, Antti
Kauppila, Joonas H.
03 / 2023
Journal of Gastrointestinal Surgery
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202304173795
https://urn.fi/URN:NBN:fi:tuni-202304173795
Kuvaus
Peer reviewed
Tiivistelmä
Background: Preoperative esophageal stenting is proposed to have a negative effect on outcomes. The aim was to compare a 5-year survival in patients undergoing esophagectomy for esophageal cancer with and without preoperative esophageal stent in a population-based nationwide cohort from Finland. The secondary outcome was 90-day mortality. Methods: This study included curatively intended esophagectomies for esophageal cancer in Finland between 1999 and 2016, with follow-up until December 31, 2019. Cox proportional hazards models provided hazard ratios (HRs) with 95% confidence intervals (CIs) of overall 5-year and 90-day mortality. Model 1 was adjusted for age, sex, year of the surgery, comorbidities, histology, pathological stage, and neoadjuvant therapy. Model 2 included also albumin level and BMI. Result: Of 1064 patients, a total of 134 patients underwent preoperative stenting and 930 did not. In both adjusted models 1 and 2, higher 5-year mortality was seen in patients with preoperative stent with HRs of 1.29 (95% CI 1.00–1.65) and 1.25 (95% CI 0.97–1.62), respectively, compared to no stenting. The adjusted HR of 90-day mortality was 2.49 (95% CI 1.27–4.87) in model 1 and 2.49 (95% CI 1.25–4.99) in model 2. When including only neoadjuvant-treated patients, those with preoperative stent had a 5-year survival of 39.2% compared to 46.4% without stent (adjusted HR 1.34, 95% CI 1.00–1.80), and a 90-day mortality rate of 8.5% and 2.5% (adjusted HR 3.99, 95% CI 1.51–10.50). Discussion: This nationwide study reports worse 5-year and 90-day outcomes in patients with preoperative esophageal stent. Since residual confounding remains possible, observed difference could be only an association rather than the cause.
Kokoelmat
- TUNICRIS-julkaisut [19236]